Drug Trial Radar · NCT06521255
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Last checked: Nov 20, 2026Latest source record: Jul 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
244
Planned (sponsor's estimate)
Start
May 7, 2024
Primary completion
Sep 2028
Study completion Dec 2029
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Randomized, Multi-center, Phase 3 Study of Tafasitamab and Lenalidomide in Combination with Gemcitabine and Oxaliplatin versus Rituximab in Combination with Gemcitabine and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphom
Conditions
- DLBCL
Interventions
TafasitamabDrug
Tafasitmab was infused intravenously
LenalidomideDrug
Lenalidomide orally
GemcitabineDrug
Gemcitabine was infused intravenously
OxaliplatinDrug
Oxaliplatin was infused intravenously
RituximabDrug
Rituximab was infused intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicity(DLT)and other adverse events (AEs) of tafasitamab and lenalidomide in combination with GemOx (TL-GemOx) assessed using CTCAE v5.0Time frame: within 28 days after therapy initiation
- PFS assessed by IRC according to Lugano 2014Time frame: 1-3 years approximately
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, China · Not yet recruiting
The First Hospital Of Jilin University
Changchun, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, China · Not yet recruiting
Chenzhou No.1 People's Hospital
Chaozhou, China · Not yet recruiting
Sichuan Province People's Hospital
Chengdu, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China · Not yet recruiting
Guangdong General Hospital
Guangzhou, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, China · Recruiting
Hangzhou First People's Hospital
Hangzhou, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China · Not yet recruiting
Shandong Cancer Hospital and Institute
Jinan, China · Not yet recruiting
Jiangxi Cancer Hospital
Nanchang, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanjing, China · Not yet recruiting
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China · Not yet recruiting
The Second Affiliated Hospital of Soochow University
Suzhou, China · Recruiting
Tianjin First Central Hospital
Tianjin, China · Not yet recruiting
Xinjiang Medical University Affiliated Cancer Hospital
Ürümqi, China · Not yet recruiting
The First Affiliated Hospital Wenzhou Medical University
Wenzhou, China · Not yet recruiting
Union Hospital Tongji Medical College
Wuhan, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.